Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07459556) titled 'A Prospective Study of Stapokibart Injection in Patients With Seasonal Allergic Rhinitis (SAR)' on March 5.

Study Type: Observational

Primary Sponsor: Chengdu Kangnuoxing Biopharma,Inc.

Condition: SAR

Intervention: Biological: Stapokibart

Recruitment Status: Not recruiting

Date of First Enrollment: March 2026

Target Sample Size: 400

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07459556

Published by HT Digital Content Services with permission from Health Daily Digest....